Genocea Biosciences appoints Howard Mayer to board
Dr. Mayer joined Shire in 2012 and is responsible for global clinical development across hematology, immunology, oncology, genetic diseases, GI/metabolic, neuroscience and ophthalmology therapeutic areas.
Previously Dr. Mayer served as chief medical officer at EMD Serono, a division of Merck KGaA, since 2009.
He held a variety of global roles at Pfizer Inc. including head of clinical development and medical affairs for Virology/Infectious Diseases.
Prior to joining Pfizer, Dr. Mayer served as director of Infectious Diseases Clinical Research at Bristol-Myers Squibb for five years.
Dr. Mayer obtained his BA from the University of Pennsylvania and his M.D. from Albert Einstein College of Medicine in New York, which was followed by an internship and residency at Mount Sinai Hospital and an Infectious Diseases fellowship at Harvard Medical School.
Dr. Mayer currently serves on the scientific advisory boards of Macrolide Pharmaceuticals and Arsanis Biosciences and has served on the board of Autism Speaks in New England since 2011 and on the board of the Melmark Charitable Foundation since 2016. ■
What to read next
LATEST MOVES FROM Massachusetts
- bluebird bio appoints Mary Lynne Hedley to board
- Welch's names Lesya Lysyj president, US
- Liberty Mutual appoints Gregg Cunningham as vice president
- Voyager Therapeutics appoints Matthew P. Ottmer as COO
- Ocular Therapeutix appoints Michael Goldstein as CMO
More inside POST